Saturday 17 October 2026
Export EVO’s income statement to Excel — free account
Evotec AG
EVO Healthcare Drug Manufacturers Specialty & Generic
Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024. In the quarter to June 2026, revenue fell 13.0%, EPS fell 328.9%, free cash flow fell 9,727.2% and total debt rose 5.48%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
1.38
0.04
−2.82%
Follow EVO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 2 | 6 | 4 | 5 | 5 | 3 | 4 | 5 | 5 |
P/E ratio |
35.39 | 91.00 | 30.41 | 92.98 | 1,048.57 | 30.94 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
2.80 | 2.95 | 4.33 | 3.25 | 4.41 | 5.29 | 2.03 | 2.25 | 0.74 | 0.64 |
P/S ratio |
5.93 | 8.16 | 6.63 | 7.70 | 9.86 | 10.81 | 3.64 | 4.90 | 1.71 | 1.23 |
P/FCF ratio |
16.99 | 0.00 | 19.45 | 350.46 | 0.00 | 2,954.32 | 132.73 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.48) | (2.00) | 0.38 | 1.46 | 2.30 | 3.77 | 2.80 | 1.48 | 0.55 | 0.76 |
P/Operating CF |
16.34 | 315.66 | 84.12 | 83.82 | 210.64 | 110.36 | (118.29) | 178.46 | 18.15 | 14.64 |
Beneish M-Score |
(2.63) | (1.69) | (2.58) | (2.23) | (2.47) | (1.83) | (3.11) | (2.91) | (2.86) | (2.62) |
P/B ratio |
4.56 | 6.33 | 5.85 | 7.20 | 6.83 | 4.85 | 2.30 | 3.25 | 1.43 | 1.19 |
Price to Tangible BV |
9.92 | 0.00 | 30.67 | 33.00 | 13.09 | 6.13 | 3.08 | 4.36 | 2.12 | 1.90 |
EV/Sales |
5.33 | 8.54 | 6.53 | 7.98 | 9.85 | 10.23 | 3.34 | 4.28 | 1.90 | 1.19 |
EV/EBITDA |
27.98 | 58.66 | 31.64 | 56.94 | 101.71 | 154.19 | 120.22 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
13.02 | 203.13 | 15.69 | 84.43 | 110.36 | 51.71 | 12.34 | (137.88) | 83.12 | (102.32) |
EV/FCF |
15.29 | (355.12) | 19.17 | 363.59 | (89.05) | 2,795.22 | 121.73 | (11.96) | (13.52) | (10.25) |
Quick Ratio |
2.13 | 0.59 | 1.08 | 2.38 | 2.84 | 3.13 | 2.80 | 1.69 | 1.61 | 1.77 |
Current Ratio |
2.31 | 0.73 | 1.27 | 2.62 | 3.16 | 3.39 | 3.18 | 1.94 | 1.98 | 2.07 |
Net Debt/EBITDA |
(2.24) | 1.65 | (0.34) | 1.14 | (0.04) | (3.23) | (2.18) | (2.79) | 0.10 | (0.64) |
Debt/Assets |
8.15% | 28.36% | 14.59% | 38.00% | 32.63% | 22.30% | 21.79% | 21.18% | 20.54% | 26.18% |
Debt/Equity |
0.13 | 0.57 | 0.27 | 0.94 | 0.66 | 0.36 | 0.41 | 0.43 | 0.41 | 0.55 |
Asset Turnover |
0.51 | 0.51 | 0.53 | 0.45 | 0.38 | 0.34 | 0.32 | 0.35 | 0.38 | 0.45 |
Operating CF/Net income |
2.45 | 0.45 | 1.86 | 1.11 | 7.15 | 0.57 | (1.16) | (0.43) | (0.09) | 0.09 |
Capex/Depreciation |
(0.83) | (0.77) | (0.89) | (0.64) | (1.76) | (1.69) | (2.18) | (2.32) | (1.28) | (0.83) |
Interest Coverage |
20.58 | 29.73 | 29.90 | 8.40 | 5.73 | 4.43 | 1.59 | — | — | — |
| 13.71% | 8.96% | 22.68% | 8.23% | 1.05% | 20.77% | (12.85%) | (7.37%) | (18.92%) | (12.00%) | |
| 8.59% | 4.80% | 11.94% | 3.82% | 0.48% | 11.82% | (7.37%) | (3.77%) | (9.41%) | (5.84%) | |
ROIC |
16.84% | 5.45% | 12.48% | 6.46% | 4.22% | 2.52% | 1.36% | (2.99%) | (9.39%) | (4.47%) |
Return on Tangible Assets |
19.77% | 265.42% | 58.45% | 7.19% | 0.79% | 17.09% | (12.67%) | (6.74%) | (16.88%) | (10.90%) |
Average Days of Receivables |
66.18 | 75.11 | 60.14 | 86.99 | 79.87 | 93.39 | 109.88 | 83.64 | 72.45 | 80.75 |
Research and Development Expense of Revenue |
11.01% | 6.84% | 9.49% | 13.09% | 12.77% | 11.68% | 10.20% | 8.77% | 6.38% | 4.76% |
Selling, General and Administrative Expense of Revenue |
16.42% | 16.45% | 15.19% | 14.91% | 15.42% | 17.06% | 20.79% | 21.71% | 23.61% | 22.32% |
Intangible Assets out of Total Assets |
0.33 | 0.53 | 0.45 | 0.32 | 0.24 | 0.13 | 0.13 | 0.13 | 0.16 | 0.18 |
Share Based Compensation of Revenue |
2.42% | 1.13% | 1.13% | 0.82% | 1.06% | 1.26% | 1.32% | 1.23% | 0.63% | 0.48% |
Graham Net Nets |
0.03 | (0.07) | (0.04) | (0.07) | (0.02) | 0.04 | 0.00 | (0.05) | (0.20) | (0.14) |
Graham Number |
1.52 | 1.62 | 3.54 | 2.36 | 1.03 | 9.20 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
2.83% | 1.10% | 3.29% | 1.08% | 0.10% | 3.23% | (6.43%) | (3.27%) | (14.38%) | (10.71%) |
Free Cash Flow Yield |
5.88% | (0.29%) | 5.14% | 0.29% | (1.12%) | 0.03% | 0.75% | (7.30%) | (8.22%) | (9.47%) |
Revenue per Share |
0.69 | 1.00 | 1.50 | 1.67 | 1.86 | 2.20 | 2.24 | 2.39 | 2.43 | 2.51 |
Operating CF per Share |
0.28 | 0.04 | 0.63 | 0.16 | 0.17 | 0.43 | 0.61 | 0.11 | 0.06 | (0.03) |
Capex per Share |
(0.04) | (0.07) | (0.11) | (0.12) | (0.37) | (0.42) | (0.54) | (0.66) | (0.40) | (0.26) |
Free Cash Flow per Share |
0.24 | (0.02) | 0.51 | 0.04 | (0.20) | 0.01 | 0.06 | (0.55) | (0.34) | (0.29) |
Cash per Share |
0.53 | 0.36 | 0.60 | 1.20 | 1.79 | 3.05 | 2.14 | 1.85 | 1.21 | 1.52 |
Shareholders Equity per Share |
0.89 | 1.29 | 1.70 | 1.78 | 2.69 | 4.90 | 3.54 | 3.43 | 2.91 | 2.59 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.89 | 1.29 | 1.70 | 1.78 | 2.69 | 4.90 | 3.54 | 3.43 | 2.91 | 2.59 |
Free Cash Flow |
63.31 | (6.86) | 151.61 | 11.55 | (62.09) | 3.90 | 22.92 | (193.76) | (121.21) | (103.62) |
Working Capital |
106.06 | (74.06) | 63.18 | 325.44 | 514.47 | 918.59 | 775.41 | 474.68 | 365.08 | 446.76 |
Capital Expenditures |
(11.23) | (19.10) | (32.91) | (35.73) | (113.17) | (140.72) | (191.07) | (233.20) | (140.93) | (93.24) |
Net Current Asset Value |
35.20 | (175.50) | (114.83) | (262.48) | (92.76) | 288.04 | 3.80 | (248.28) | (300.84) | (155.34) |
EV/EBIT |
27.98 | 58.66 | 31.64 | 56.94 | 101.71 | 154.19 | 120.22 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.06 | 0.07 | 0.07 | 0.07 | 0.20 | 0.19 | 0.24 | 0.28 | 0.16 | 0.10 |
Price to Operating Income |
31.10 | 56.05 | 32.11 | 54.89 | 101.80 | 162.97 | 131.09 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.28 | 0.29 | 0.35 | 0.21 | 0.17 | 0.15 | 0.13 | 0.12 | 0.12 | 0.18 |
Cash ROIC |
15.51% | (0.99%) | 18.69% | 0.83% | (3.23%) | 0.12% | 0.91% | (8.13%) | (6.43%) | (5.27%) |
Accounts Receivable Turnover |
6.32 | 6.27 | 6.67 | 5.20 | 4.68 | 4.68 | 3.72 | 3.91 | 4.73 | 4.84 |
Accounts Payable Turnover |
8.75 | 9.26 | 9.39 | 9.78 | 10.24 | 8.21 | 6.46 | 5.30 | 6.20 | 9.18 |
Inventory Turnover |
28.45 | 26.46 | 36.86 | 37.51 | 31.10 | 23.98 | 19.64 | 20.24 | 22.00 | 22.82 |
Average Days of Payables |
41.33 | 54.37 | 43.15 | 36.46 | 41.39 | 56.80 | 61.49 | 80.85 | 45.91 | 35.06 |
Days of Inventory on Hand |
14.83 | 18.80 | 7.84 | 12.51 | 13.22 | 20.18 | 18.85 | 18.59 | 16.65 | 15.87 |
Average Receivables |
28.82 | 46.47 | 66.49 | 96.11 | 122.19 | 156.15 | 212.72 | 216.07 | 182.49 | 184.26 |
Average Payables |
13.40 | 21.38 | 33.12 | 35.93 | 41.84 | 67.25 | 94.19 | 123.93 | 119.10 | 83.05 |
Average Inventory |
4.12 | 7.48 | 8.44 | 9.36 | 13.78 | 23.02 | 30.97 | 32.43 | 33.55 | 33.42 |
Average Assets |
354.61 | 571.52 | 832.90 | 1,117.11 | 1,496.84 | 2,157.74 | 2,511.33 | 2,408.04 | 2,253.68 | 2,004.34 |
Average Common Equity |
222.25 | 305.86 | 438.38 | 518.03 | 679.99 | 1,227.82 | 1,440.38 | 1,231.45 | 1,121.40 | 975.68 |
Columns are period end dates